Papi, Alessio <br/><br/>
RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells.  [electronic resource] 

 -  Cancer letters  Nov 2010 
 - 65-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2010.04.026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Colonic Neoplasms--genetics<br/>Cyclooxygenase 2--metabolism<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>HCT116 Cells<br/>Humans<br/>Ligands<br/>Matrix Metalloproteinase 2--metabolism<br/>Matrix Metalloproteinase 9--metabolism<br/>Neoplasm Invasiveness<br/>PPAR gamma--agonists<br/>Pioglitazone<br/>Response Elements--drug effects<br/>Retinoid X Receptor gamma--agonists<br/>Thiazolidinediones--pharmacology<br/>Tissue Inhibitor of Metalloproteinase-1--metabolism<br/>Tissue Inhibitor of Metalloproteinase-2--metabolism<br/>Transcriptional Activation--drug effects<br/>Tretinoin--analogs & derivatives